Top Page
Diagnos
(ADK)
Diagnos (ADK) vs. iShares MSCI Canada ETF (EWC)
Diagnos Business Overview & Revenue Model
Diagnos Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.51K | 103.80K | 170.16K | 438.83K | 267.07K | 331.52K |
| Gross Profit | -1.23M | -943.56K | 35.80K | -418.30K | -347.53K | -473.45K |
| EBITDA | -3.98M | -3.56M | -2.45M | -2.10M | -2.45M | -1.93M |
| Net Income | -4.68M | -4.29M | -3.12M | -2.61M | -2.05M | -3.38M |
Balance Sheet | ||||||
| Total Assets | 2.05M | 3.64M | 663.79K | 1.54M | 1.95M | 2.43M |
| Cash, Cash Equivalents and Short-Term Investments | 1.66M | 3.24M | 219.01K | 920.91K | 1.36M | 1.87M |
| Total Debt | 2.50M | 3.07M | 3.19M | 1.19M | 471.68K | 337.55K |
| Total Liabilities | 2.85M | 3.40M | 3.72M | 1.66M | 818.19K | 614.78K |
| Stockholders Equity | -801.73K | 233.11K | -3.05M | -113.51K | 1.13M | 1.82M |
Cash Flow | ||||||
| Free Cash Flow | -3.79M | -3.65M | -2.16M | -2.07M | -1.40M | -2.66M |
| Operating Cash Flow | -3.78M | -3.64M | -2.15M | -2.04M | -1.36M | -2.64M |
| Investing Cash Flow | -996.54K | -3.11M | -14.02K | 503.52K | 262.93K | -759.98K |
| Financing Cash Flow | 4.75M | 6.62M | 2.08M | 1.60M | 882.82K | 3.83M |
Diagnos Technical Analysis
Diagnos Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$35.14M | -6.98 | ― | ― | -47.10% | -19.32% | |
| ― | C$11.63M | -1.61 | -1143.80% | ― | -64.23% | 18.42% | |
| ― | C$11.49M | ― | ― | ― | 12.44% | 74.38% | |
| ― | $14.89M | -2.48 | ― | ― | ― | 21.61% | |
| ― | C$71.54M | ― | -202.19% | ― | ― | 40.17% |
Diagnos Corporate Events
Diagnos Inc. has announced its intention to extend the exercise period of 1,125,000 stock warrants, initially set to expire on November 9, 2025, to a new date of August 5, 2026, pending approval from the TSX Venture Exchange. This extension aims to provide warrant holders with additional time to exercise their options, potentially impacting the company’s financial strategy and market positioning.
The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.
DIAGNOS has announced its participation in the Centurion One Capital 3rd Annual Bahamas Summit, where CEO André Larente will present and engage with investors. The event provides a platform for DIAGNOS to showcase its growth potential, supported by recent regulatory advancements, to a global audience of growth investors.
The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.
DIAGNOS Inc. has successfully completed its annual surveillance audit under the Medical Device Single Audit Program (MDSAP), confirming full compliance with quality and regulatory standards. This achievement strengthens DIAGNOS’ position in regulatory submissions and supports its mission to aid healthcare professionals in early detection of critical health issues. The renewed certification reflects the company’s commitment to scaling its SaaS-based AI platform globally, aligning with its expanding strategy and accelerating approvals with Health Canada, the FDA, and the SFDA.
The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.
DIAGNOS Inc. announced the results of its annual shareholders’ meeting, where André Larente, Robert Dunn, Michael Braeuel, and Philippe Couillard were elected as directors. Grant Thornton LLP was appointed as the auditor for the fiscal year ending March 31, 2026. Additionally, the company granted 1,100,000 stock options to two directors, replacing expiring options, with an exercise price of $0.26 per share, subject to regulatory compliance. These developments indicate DIAGNOS’s ongoing commitment to strengthening its leadership and financial oversight, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.
Diagnos Inc. has successfully closed a non-brokered private placement, raising $100,000 through the issuance of 10 units priced at $10,000 each. The funds will be used primarily for product development, commercialization of AI-based screening services, and general administrative expenses. The transaction involved a director of the company, considered a related party, but was exempt from certain regulatory requirements due to its size. The private placement is still subject to necessary approvals, including from the TSX Venture Exchange.
The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.
DIAGNOS Inc. announced a non-brokered private placement of 10 units at $10,000 each, totaling $100,000. The funds will primarily support product development and commercialization of AI-based screening services. A director has committed to subscribing to all units, and the placement is subject to necessary approvals.
The most recent analyst rating on (TSE:ADK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Diagnos stock, see the TSE:ADK Stock Forecast page.
Diagnos Inc. has announced its intention to extend the exercise period for 650,000 stock warrants issued as part of a non-brokered private placement, pending approval from the TSX Venture Exchange. The new expiry date is proposed to be August 5, 2026, with all other terms remaining unchanged. Additionally, Diagnos corrected a previous announcement regarding the expiry date of another set of warrants, clarifying the new date as August 5, 2026, instead of February 27, 2029. This move reflects the company’s ongoing efforts to manage its financial instruments effectively, potentially impacting investor relations and market perceptions.
Diagnos Inc. has announced its intention to extend the exercise period of over 1.4 million stock warrants from an initial expiry date of August 27, 2025, to February 27, 2029, pending approval from the TSX Venture Exchange. This extension is part of a strategic move to maintain favorable conditions for stakeholders, with all other warrant terms remaining unchanged. The amendment has been reviewed and approved by the board, ensuring alignment with the corporation’s and shareholders’ best interests.